A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer - Summary - MDSpire

A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer

  • By

  • Dan Zhou

  • Beibei Ran

  • Lingkai Kong

  • Yan Liu

  • Lingjun Xiao

  • Xiangmei Chen

  • Wencui Liu

  • Xiao Li

  • Jing Zhang

  • Jiahui Zhang

  • Hao Wu

  • Guang Zhang

  • Xiaosong Gu

  • Wenjie Zhang

  • Junhua Wu

  • Chunping Jiang

  • June 15, 2026

  • 0 min

Share

Objective:

To engineer an oncolytic adenovirus that mitigates T cell exhaustion and enhances the efficacy of anti-PD-1 and CAR-T therapies in colorectal cancer.

Approach:
    Key Findings:
    • ADV-PTD4-D3 improved tumor control and induced robust antigen-specific immunological memory, suggesting a potential shift in treatment paradigms.
    • The treatment reversed functional exhaustion of CD8+ T cells and enhanced their infiltration into tumors, addressing critical barriers to effective therapy.
    • ADV-PTD4-D3 significantly potentiated the efficacy of PD-1 blockade and CAR-T cell therapy, indicating its role as a valuable adjunct in cancer treatment.
    Interpretation:

    Engineering oncolytic viruses to locally modulate T cell exhaustion pathways may enhance antitumor immunity in colorectal cancer, paving the way for innovative therapeutic strategies.

    Limitations:
    • The study primarily utilized murine models, which may not fully replicate human responses.
    • Long-term effects and potential off-target effects in humans remain to be evaluated, necessitating further clinical investigation.
    Conclusion:

    The findings support the potential of ADV-PTD4-D3 as a strategy to enhance T cell responses and improve outcomes in colorectal cancer treatment.

Original Source(s)

A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer

  • by Dan Zhou, Beibei Ran, Lingkai Kong, Yan Liu, Lingjun Xiao, Xiangmei Chen, Wencui Liu, Xiao Li, Jing Zhang, Jiahui Zhang, Hao Wu, Guang Zhang, Xiaosong Gu, Wenjie Zhang, Junhua Wu, Chunping Jiang

  • June 15, 2026

Related Content

Survival prediction in colorectal cancer liver metastases using machine learning with SHAP-based interpretation

A study on risk prediction of decline in self-care ability one month after discharge in postoperative colorectal cancer patients based on routine clinical indicators

Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study